BCR-ABL regulates ATF5 expression independent of IL-3. (A) qRT-PCR analysis monitoring Atf5 expression in 32D or 32D/BCR-ABL cells cultured in the presence or absence of IL-3. Error bars represent SD. (B) Immunoblot analysis of ATF5 levels in 32D or 32D/BCR-ABL cells cultured in the presence or absence of IL-3. (C) qRT-PCR monitoring Atf5 expression in 32D/BCR-ABL or 32D/BCR-ABL(T315I) cells treated in the absence or presence of imatinib (10μM for 16 hours). Error bars represent SD. (D) Immunoblot analysis of ATF5 levels in 32D/BCR-ABL or 32D/BCR-ABL(T315I) cells in the absence or presence of imatinib (10μM for 16 hours). (E) qRT-PCR analysis monitoring ATF5 expression in K562 cells treated with or without imatinib (10μM for 48 hours). Error bars represent SD. (F) Immunoblot analysis of ATF5 levels in K562 cells treated with or without imatinib (10μM for 48 hours). (G) qRT-PCR monitoring of ATF5 expression in human peripheral blood cells isolated from chronic-phase CML patients (n = 3). Cells were treated in the absence or presence of imatinib (10μM for 16 hours). Error bars represent SE. *P < .05; **P > .05.